Shots:
- Oncolytics is expecting to receive the final PanCAN grant payment later this quarter following completion of certain activities in Cohort 5 of its P-I/II (GOBLET) study, alongside an update on the timing of clinical data release for pelareorep
- The final Cohort 4 results are expected in Q4’26, which evaluates pelareorep with atezolizumab in 2L & later squamous cell anal carcinoma, while initial Cohort 5 results in first-line metastatic pancreatic ductal adenocarcinoma are anticipated in H1’27, potentially extending due to ongoing treatment & follow-up
- Enrollment across GOBLET is complete, and each cohort that enrolled the required number of patients met its prespecified efficacy success criteria. Oncolytics is winding down study infrastructure while continuing remaining patient follow-up
Ref: Globenewswire | Image: Oncolytics Biotech | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
